NCT06789458 Assessment of Pro-Resolution Mediator Levels in Periodontitis Stage III and IV Before and After Periodontal Therapy
| NCT ID | NCT06789458 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Peridontal Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 22 participants |
| Start Date | 2022-10-15 |
| Primary Completion | 2025-10-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 22 participants in total. It began in 2022-10-15 with a primary completion date of 2025-10-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess Pro-Resolution Mediator levels during non-surgical periodontal therapy in individuals with Stage III and IV periodontitis, comparing them to healthy subjects. Periodontitis, a chronic inflammatory condition affecting tooth-supporting tissues, can lead to tooth loss and systemic complications. Understanding the role of pro-resolving lipid mediators in inflammation resolution may offer insights into therapeutic benefits associated with these mediators.
Eligibility Criteria
Inclusion Criteria: Inclusion criteria: 1. Adult patients above 18 years old. 2. Interdental CAL at site of greatest loss ≥5 mm or extending to middle third of the root. 3. Interdental CAL at site of greatest loss ≥8 mm or extending to apical third of the root. 4. Probing depth ≥6 mm. 5. Vertical bone loss ≥3 mm. 6. Tooth loss due to periodontitis of ≤4 teeth. (Periodontitis Stage III) 7. Tooth loss due to periodontitis of ≥5 teeth. (Periodontitis Stage IV) 8. Furcation involvement Class II or III Moderate ridge defect. \- Exclusion Criteria: * 1\. Pregnancy or lactation. 2. Smoking more than 20 cigarettes. 3. Immuno-inflammatory conditions of the skin and oral mucosa 4. systemic conditions affecting bone turnover and periodontal health status (e.g. endocrine and connective tissue diseases, bisphosphonate antiresorptive therapy, gastrointestinal diseases related to nutrition and mineral metabolism) 5. Periodontal or orthodontic treatment at least 6 months before the start of the study 6. Use of anti-inflammatory and antimicrobial agents within 3 months before sampling Inclusion criteria for healthy group: 1. Systemically healthy patients. 2. Patients with an age range between 16 to 80 years. 3. Patients have a minimum of 20 teeth. 4. Less than 10% bleeding sites with probing depths ≤3 mm. 5. absence of erythema, oedema.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06789458 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Peridontal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06789458 currently recruiting?
Yes, NCT06789458 is actively recruiting participants. Contact the research team at husam.ghazi@dentistry.cu.edu.eg for enrollment information.
Where is the NCT06789458 trial being conducted?
This trial is being conducted at Manial, Egypt, Cairo, Egypt.
Who is sponsoring the NCT06789458 clinical trial?
NCT06789458 is sponsored by Cairo University. The trial plans to enroll 22 participants.